The Impact of Fasting during Ramadan on the Glycemic Control of Patients with Type 2 Diabetes Mellitus

Abstract

Background:

Millions of Muslims fast from dawn until dusk during the annual Islamic holy month of Ramadan. Most of the studies evaluating biochemical changes in diabetic patients during Ramadan showed little changes in the glycemic control. In this study, our aim was to assess the impact of fasting during Ramadan on glycemic control in patients with type 2 diabetes.

Methods and design:

We examined 122 patients with type 2 diabetes (82 female, 40 male, age 56.93±9.57 years) before and after the Ramadan. 66.4% of the patients were treated with oral antidiabetic (OAD) alone, 6.5% with a combination of insulin plus OAD and 19.7% with insulin alone. 88 of 122 patients fasted during Ramadan (26.98±5.93 days). Weight, body mass index (BMI), waist circumference, blood pressure, fasting plasma glucose (FPG), postprandial glucose (PPG), fructosamine, HbA1c, fasting insulin and lipid parameters were measured.

Results:

The frequencies of both severe hyperglycemia and hypoglycemia were higher in the fasting group, but the difference was not significant (p=0.18). Weight, BMI, waist circumference, blood pressure, FPG (143.38±52.04 vs. 139.31±43.47 mg/dl) PPG (213.40±98.56 vs. 215.66+109.31 mg/dl) , fructosamine (314.18±75.40 vs. 314.49±68.36 µmol/l), HbA1c (6.33±0.98 vs. 6.22±0.92%) and fasting insulin (12.61±8.94 vs. 10.51±6.26 µU/ml) were unchanged in patients who fasted during Ramadan. Microalbuminuria significantly decreased during Ramadan (132.85±197.11 vs. 45.03±73.11 mg/dl).

Conclusions:

In this study, we concluded that fasting during Ramadan did not worsen the glycemic control of patients with type 2 diabetes.

Key words

ramadan - diabetes

• References

• 1 Salti I, Benard E, Detournay B et al. EPIDIAR study group. A populationbased study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004; 27: 2306-2311
• 2 Akanji AO, Mojiminiyi OA, Abdella N. Beneficial changes in serum Apo A-1 and its ratio to apoB and HDL in stable hyperlipidaemic subjects after Ramadan fasting in Kuwait. Eur J Clin Nutr 2000; 54: 508-513
• 3 Mafauzy M, Wan Mohamad WB, Zulkifli A et al. A study of fasting diabetic patients during the month of Ramadan. Med J Malaysia 1990; 45: 14-17
• 4 Uysal AR, Erdogan MF, Sahin G et al. Clinical and metabolic effects of fasting in 41 type 2 diabetic patients during Ramadan (Letter). Diabetes Care 1998; 21: 2033-2034
• 5 Yarahmadi SH, Larijani B, Bastanhagh MH et al. Metabolic and clinical effects of Ramadan fasting in patients with type II diabetes. J Coll Physicians Surg Pak 2003; 13: 329-332
• 6 Laajam MA. Ramadan fasting and noninsulin-dependent diabetes: effect on metabolic control. East Afr Med J 1990; 67: 732-736
• 7 Katibi IA, Akande AA, Bojuwoye BJ et al. Blood sugar control among fasting Muslims with type 2 diabetes mellitus in Ilorin. Niger J Med 2001; 10: 132-134
• 8 Elmehdawi RR, Mukhtad NA, Allaghi NI et al. Fasting of Ramadan in peoples with diabetes in Benghazi Libya: an exploratory study. Libyan J Med 2010; 4: 5
• 9 Belkhadir J, el Ghomari H, Klöcker N et al. Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide. BMJ 1993; 307: 292-295
• 10 Al Sifri S, Basiounny A, Echtay A et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract 2011; 65: 1132-1140
• 11 Devendra D, Gohel B, Bravis V et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009; 63: 1446-1450
• 12 Hassanein M, Hanif W, Malik W et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin 2011; 27: 1367-1374
• 13 Mafauzy M. Repaglinide vs. glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract 2002; 58: 45-53
• 14 Cesur M, Corapcioglu D, Gursoy A et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract 2007; 75: 141-147
• 15 Sari R, Balci MK, Akbas SH et al. The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocr Res 2004; 30: 169-177